Create Free Account

By creating account you will get access to hot stocks & personalised emails

IQVIA Holdings Inc

Healthcare US IQV

194.93USD
-4.46(2.24%)

Last update at 2024-12-30T14:54:00Z

Day Range

195.04198.29
LowHigh

52 Week Range

167.42241.86
LowHigh

Fundamentals

  • Previous Close 199.39
  • Market Cap41062.50M
  • Volume38240
  • P/E Ratio37.82
  • Dividend Yield-%
  • EBITDA2715.00M
  • Revenue TTM14855.00M
  • Revenue Per Share TTM80.44
  • Gross Profit TTM 5028.00M
  • Diluted EPS TTM5.95

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 1363.00M 1128.00M 373.00M 352.00M 328.00M
Minority interest 0.00000M -5.00000M 29.00M 36.00M 25.00M
Net income 1091.00M 966.00M 279.00M 191.00M 259.00M
Selling general administrative 2071.00M 1964.00M 1789.00M 1734.00M 1716.00M
Selling and marketing expenses - - - - -
Gross profit 5028.00M 4641.00M 3859.00M 3788.00M 3666.00M
Reconciled depreciation 1130.00M 1264.00M 1287.00M 1202.00M 1141.00M
Ebit 1799.00M 1393.00M 731.00M 777.00M 812.00M
Ebitda 2937.00M 2813.00M 2141.00M 2100.00M 1953.00M
Depreciation and amortization 1138.00M 1420.00M 1410.00M 1323.00M 1141.00M
Non operating income net other -32.00000M 116.00M 65.00M 13.00M 16.00M
Operating income 1799.00M 1393.00M 731.00M 777.00M 741.00M
Other operating expenses 12583.00M 12461.00M 10576.00M 10236.00M 9603.00M
Interest expense 416.00M 375.00M 416.00M 447.00M 414.00M
Tax provision 260.00M 163.00M 72.00M 116.00M 59.00M
Interest income 403.00M 6.00M 6.00M 9.00M 8.00M
Net interest income -403.00000M -369.00000M -410.00000M -438.00000M -406.00000M
Extraordinary items - - - 0.00000M 35.00M
Non recurring 28.00M 20.00M 52.00M 75.00M 68.00M
Other items - - - - -
Income tax expense 260.00M 163.00M 72.00M 116.00M 59.00M
Total revenue 14410.00M 13874.00M 11359.00M 11088.00M 10412.00M
Total operating expenses 3201.00M 3228.00M 3076.00M 2936.00M 2857.00M
Cost of revenue 9382.00M 9233.00M 7500.00M 7300.00M 6746.00M
Total other income expense net -436.00000M -265.00000M -358.00000M -425.00000M -75.00000M
Discontinued operations - - - - -
Net income from continuing ops 1091.00M 971.00M 301.00M 236.00M 269.00M
Net income applicable to common shares 1091.00M 966.00M 279.00M 191.00M 259.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 25337.00M 24689.00M 24564.00M 23251.00M 22549.00M
Intangible assets 4820.00M 4943.00M 5205.00M 5514.00M 5951.00M
Earning assets - - - - -
Other current assets 561.00M 521.00M 563.00M 451.00M 322.00M
Total liab 19572.00M 18647.00M 18284.00M 16988.00M 15595.00M
Total stockholder equity 5765.00M 6042.00M 6001.00M 6003.00M 6714.00M
Deferred long term liab 464.00M 410.00M 338.00M 646.00M 736.00M
Other current liab 313.00M 344.00M 344.00M 319.00M 1990.00M
Common stock 10898.00M 10777.00M 11095.00M 11049.00M 10901.00M
Capital stock 10898.00M 10777.00M 11095.00M 11049.00M 10901.00M
Retained earnings 3334.00M 2243.00M 1277.00M 998.00M 807.00M
Other liab 911.00M 1059.00M 971.00M 1072.00M 1140.00M
Good will 13921.00M 13301.00M 12654.00M 12159.00M 11800.00M
Other assets 590.00M 615.00M 1133.00M 346.00M 344.00M
Cash 1216.00M 1366.00M 1814.00M 837.00M 891.00M
Cash and equivalents 1216.00M 1366.00M 1814.00M 837.00M 891.00M
Total current liabilities 5578.00M 5241.00M 4558.00M 3945.00M 3534.00M
Current deferred revenue 1797.00M 1825.00M 1252.00M 1014.00M 1007.00M
Net debt 11795.00M 11072.00M 11090.00M 11204.00M 10116.00M
Short term debt 152.00M 91.00M 149.00M 100.00M 100.00M
Short long term debt 152.00M 91.00M 149.00M 100.00M 100.00M
Short long term debt total 13011.00M 12438.00M 12904.00M 12041.00M 11007.00M
Other stockholder equity -7740.00000M -6572.00000M -6166.00000M -5733.00000M -4770.00000M
Property plant equipment 863.00M 903.00M 482.00M 458.00M 434.00M
Total current assets 4981.00M 4763.00M 5090.00M 4126.00M 3874.00M
Long term investments 162.00M 164.00M 84.00M 87.00M 142.00M
Net tangible assets -12976.00000M -12202.00000M -11858.00000M -11670.00000M -11037.00000M
Short term investments 93.00M 111.00M 88.00M 62.00M 47.00M
Net receivables 2960.00M 2609.00M 2466.00M 2638.00M 2463.00M
Long term debt 12595.00M 12034.00M 12384.00M 11545.00M 10907.00M
Inventory 151.00M 156.00M 159.00M 138.00M 151.00M
Accounts payable 3316.00M 2981.00M 2813.00M 2512.00M 437.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - 279.00M 260.00M 240.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -727.00000M -406.00000M -205.00000M -311.00000M -224.00000M
Additional paid in capital - - - - -
Common stock total equity 10898.00M 10777.00M 11095.00M 11049.00M 10901.00M
Preferred stock total equity - - - - -
Retained earnings total equity 3334.00M 2243.00M 1277.00M 998.00M 807.00M
Treasury stock - -6572.00000M -6166.00000M -5733.00000M -4770.00000M
Accumulated amortization - - - - -
Non currrent assets other 472.00M 491.00M 386.00M 227.00M 239.00M
Deferred long term asset charges - - - 119.00M 109.00M
Non current assets total 20356.00M 19926.00M 19474.00M 19125.00M 18675.00M
Capital lease obligations 264.00M 313.00M 371.00M 396.00M -
Long term debt total 12595.00M 12034.00M 12384.00M 11545.00M 10907.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2006.00000M -10.00000M -2.00000M -22.00000M -23.00000M
Change to liabilities 299.00M 835.00M 170.00M 235.00M 250.00M
Total cashflows from investing activities -2006.00000M -2103.00000M -796.00000M -1190.00000M -810.00000M
Net borrowings 936.00M 70.00M 309.00M 700.00M 993.00M
Total cash from financing activities -329.00000M -1235.00000M -217.00000M -276.00000M -452.00000M
Change to operating activities 7.00M -15.00000M -146.00000M -92.00000M -66.00000M
Net income 1091.00M 971.00M 308.00M 227.00M 284.00M
Change in cash -150.00000M -448.00000M 977.00M -54.00000M -68.00000M
Begin period cash flow 1366.00M 1814.00M 837.00M 891.00M 959.00M
End period cash flow 1216.00M 1366.00M 1814.00M 837.00M 891.00M
Total cash from operating activities 2260.00M 2942.00M 1959.00M 1417.00M 1254.00M
Issuance of capital stock - - - - 15.00M
Depreciation 1130.00M 1264.00M 1287.00M 1202.00M 1141.00M
Other cashflows from investing activities -1332.00000M 5.00M -178.00000M -586.00000M -328.00000M
Dividends paid - - 13.00M 18.00M 4076.00M
Change to inventory - -17.00000M -229.00000M -116.00000M -184.00000M
Change to account receivables -421.00000M -138.00000M 255.00M -124.00000M -297.00000M
Sale purchase of stock -1168.00000M -406.00000M -447.00000M -949.00000M -1405.00000M
Other cashflows from financing activities 3498.00M 1862.00M 2729.00M 4348.00M 8075.00M
Change to netincome 108.00M 15.00M -113.00000M -44.00000M -76.00000M
Capital expenditures 674.00M 640.00M 616.00M 582.00M 459.00M
Change receivables -421.00000M -138.00000M 255.00M -122.00000M -297.00000M
Cash flows other operating 38.00M 576.00M 34.00M -94.00000M -59.00000M
Exchange rate changes - - - - -60.00000M
Cash and cash equivalents changes -75.00000M -396.00000M 946.00M -49.00000M -68.00000M
Change in working capital -84.00000M 680.00M 459.00M 19.00M -106.00000M
Stock based compensation 194.00M 170.00M 95.00M 146.00M 113.00M
Other non cash items 44.00M -5.00000M -14.00000M -20.00000M -1.00000M
Free cash flow 1586.00M 2302.00M 1343.00M 835.00M 795.00M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IQV
IQVIA Holdings Inc		 -4.46 2.24% 194.93 37.82 19.68 2.76 7.20 3.61 17.03
TMO
Thermo Fisher Scientific Inc		 -8.67 1.65% 517.40 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.26 1.41% 227.84 29.09 28.01 5.67 3.20 6.00 19.09
IDXX
IDEXX Laboratories Inc		 -7.55 1.82% 407.38 49.99 45.66 11.29 27.85 11.46 34.46
A
Agilent Technologies Inc		 -2.21 1.63% 133.33 31.97 25.84 6.23 6.96 6.62 23.01

Reports Covered

Stock Research & News

View All

Profile

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.

IQVIA Holdings Inc

4820 Emperor boulevard, Durham, NC, United States, 27703

Key Executives

Name Title Year Born
Ms. Keriann Cherofsky Sr. VP, Corp. Controller & Principal Accounting Officer 1984
Mr. Ari Bousbib Chairman, Pres & CEO 1961
Mr. Ronald E. Bruehlman Exec. VP & CFO 1961
Mr. Eric M. Sherbet Exec. VP, Gen. Counsel & Sec. 1964
Mr. Kevin C. Knightly Pres of Corp. Strategy & Enterprise Networks 1961
Dr. Jeffrey A. Spaeder Sr. VP, Global Chief Medical & Scientific Officer NA
Mr. Karl Guenault Sr. VP & Chief Information Officer NA
Andrew Markwick Sr. VP of Investor Relations NA
Mr. Nicholas Childs Sr. VP, Investor Relations & Corp. Communications NA
Ms. Trudy Stein Chief HR Officer & Exec. VP NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.